Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies.

ABSTRACT: Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated. To study whether neutrophil-mediated destruction of B cell malignancies can be added to the arsenal of effector mechanisms, we chimerized a panel of five previously described murine CD20 antibodies to the human IgG1, IgA1 and IgA2 isotype. Of this panel, we assessed in vitro antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and direct cell death induction capacity and studied the efficacy in two different in vivo mouse models. IgA antibodi

SUBMITTER: Evers M 

PROVIDER: S-EPMC7531568 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature